New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Vyome Holdings, Inc.

HIND

Healthcare Biotechnology

Vyome Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $319,700.00, up 24.4% from fiscal 2024.

Revenue
+67.6%
EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

1.20 0.25 −17.24%
Market cap
$10.2M
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
4/9
ROIC
0.00%
Net debt / EBITDA
0.5×
Payout ratio
—

Vyome Holdings, Inc. (HIND) EV/Sales

Alert me on EV/Sales

As of Nov 20, 2026, Vyome Holdings, Inc. (HIND) trades at a EV/Sales of 12.7×. Over the past ten years it has ranged from −10.7× (September 2025) to 440,315,327× (June 2017); the current reading is higher than 37% of that period. That is above the Biotechnology industry median of 8.0× and above the Healthcare sector median of 3.1×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 48.5× 5,398.46%
FY2024 0.9× —
FY2023 −0.3× —
FY2022 0.5× —
FY2021 −1.7× —
FY2020 451,057× (80.98%)
FY2019 2,371,429× (37.06%)
FY2018 3,767,621× (96.41%)
FY2017 104,890,150× 5.78%
FY2016 99,162,852× 118.34%

Quarterly newest first

Period EV/Sales Change
Sep 2026 45.3× (18.44%)
Jun 2026 55.5× 51.76%
Mar 2026 36.6× (24.60%)
Dec 2025 48.5× 94.83%
42 more quarters

Against its own ten years

Low −10.7× High 440,315,327×
Ten-year median 338,101×
Current reading's percentile 19

EV/Sales against peers

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on HIND